Alexion Pharmaceuticals (ALXN) : Net money flow in Alexion Pharmaceuticals (ALXN) was negative ($72.96 million) and the inflow of money on uptick was $59.43 million, whereas, the outflow of money on downticks amounted to $132.39 million on Thursday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.45. The block trades show that the large investors, were aggressive sellers in the stock. The total value of block trades on upticks was only $2.77 million. On the other hand, the total value of block trades done on downticks was $70.37 million. The ratio of uptick to downtick block trades was 0.04. The money flow in block trades was negative ($67.6). Alexion Pharmaceuticals (ALXN) gained $2.22 cent during the day and reached $123.34, a gain of 1.83% over the previous day.
Alexion Pharmaceuticals (ALXN) : Average target price received by Alexion Pharmaceuticals (ALXN) is $193.47 with an expected standard deviation of $24.47. The most aggressive target on the stock is $221, whereas the most downbeat target is $145. 15 financial analysts are currently covering the stock. The stock has recorded a 20-day Moving Average of 0.56% and the 50-Day Moving Average is 9.8%.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $122.20 and $121.90 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $125.54. The buying momentum continued till the end and the stock did not give up its gains. It closed at $123.34, notching a gain of 1.83% for the day. The total traded volume was 2,812,834 . The stock had closed at $121.12 on the previous day.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.